PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33002595-7	2020	Oppositely, fluvoxamine and sertraline, agents belonging to the class of selective serotonin reuptake inhibitor, upregulated the PGE1-stimulated release of both OPG and IL-6.	Fluvoxamine	12-23	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	161-164	
34392133-7	2021	Not the selective norepinephrine reuptake inhibitor reboxetine but the selective serotonin reuptake inhibitors fluvoxamine and sertraline upregulated the PGD2-induced osteoprotegerin release, which was further amplified by morphine.	Fluvoxamine	111-122	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	167-182	
33646885-5	2021	Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), reduced the BMP-4-stimulated OPG release, whereas a selective and specific norepinephrine reuptake inhibitor, reboxetine failed to affect the OPG release.	Fluvoxamine	0-11	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	91-94	
33002595-10	2020	SB203880, an inhibitor of p38 MAP kinase, suppressed the amplifying effects by duloxetine or fluvoxamine on the PGE1-stimulated release of OPG and IL-6.	Fluvoxamine	93-104	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	139-142